Target intelligence / Profile preview

Dynamin-1-like protein (DRP1)

Target
DRP1
Molecular classification
Enzyme, GTPase, Dynamin superfamily
01

Overview

Dynamin-1-like protein (DNM1L), commonly known as dynamin-related protein 1 (DRP1), is a large GTPase belonging to the dynamin superfamily that plays a central role in regulating mitochondrial and peroxisomal fission. Under physiological conditions, DRP1 is recruited from the cytosol to the outer mitochondrial membrane by adaptor proteins (such as Mff, Fis1, and MiD49/MiD51) where it oligomerizes to form ring-like structures that constrict and sever the membrane in a GTP-dependent manner. This process is critical for maintaining mitochondrial network morphology, quality control via mitophagy, and cellular homeostasis. Dysregulation of DRP1, particularly excessive activation leading to pathological mitochondrial fragmentation, is implicated in the pathogenesis of neurodegenerative diseases (such as Alzheimer's and Parkinson's), cardiovascular diseases (including ischemia-reperfusion injury), and metabolic disorders. Conversely, loss-of-function mutations in the DNM1L gene cause rare, severe neurodevelopmental disorders. Consequently, DRP1 has emerged as a promising therapeutic target, with several small-molecule and peptide inhibitors (such as Mdivi-1, DRP1i27, and P110) being investigated in preclinical models to restore mitochondrial dynamics and protect against cell death.

Other names
Dynamin-related protein 1DRP1DLP1Dynamin-like protein 1Dnm1p/Vps1p-like proteinDVLPDYMPLEEMPFEMPF1HDYNIVOPA5
02

Mechanism of action

Inhibition of GTPase activity or disruption of recruitment to the mitochondrial outer membrane to prevent mitochondrial fission

03

Biological functions

Mitochondrial fissionPeroxisomal fissionApoptosisNecrosisMitophagyCell cycle regulation
04

Disease associations

Neurodegenerative diseaseCancerCardiovascular diseaseIschemia-reperfusion injuryEncephalopathyOptic atrophy
05

Safety considerations

Impairment of basal mitochondrial quality control and mitophagyPotential systemic toxicity in high-energy tissues like the heart and brain with chronic useOff-target effects of existing inhibitors such as complex I inhibition by Mdivi-1Developmental toxicity and embryonic lethality
06

Interacting drugs

4 more in the full profile.

07

Biomarkers

Mitochondrial morphologyDRP1 phosphorylation statusReactive oxygen species levelsCytochrome c release

Beyond the preview

Go deeper on Dynamin-1-like protein (DRP1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dynamin-1-like protein (DRP1).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call